
    
      This study is a randomized double-blind controlled clinical trial with postmenopausal women
      aged between 45 and 55 years with chronic arthralgia related to climacteric. They will be
      evaluated climacteric symptoms, pain intensity, level of physical activity, pain
      catastrophising, depression, anxiety, quality of sleep and quality of life. The volunteers
      will be randomized, in the proportion 1:1, to treatment with either 0,625 mg conjugated
      equine estrogen, via oral administration, for 12 weeks or placebo, via oral administration,
      for 12 weeks. The randomization will be performed by a computer-generated random numbers
      list. The investigators will be blinded until completion of 12 weeks. Evaluation of
      climacteric symptoms, pain intensity, level of physical activity, pain catastrophising,
      depression, anxiety, quality of sleep and quality of life will be performed in the hospital
      at baseline, 1, 2, 3, 6 months and 15 days. In each visit, participants will be evaluated
      about adverse effects such as diarrhea, nausea and vomit.
    
  